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Abstract
Objective—To accurately assess the benefits of tobacco control interventions and to better 
inform decision makers, knowledge of medical expenditures by age, gender, and smoking status is 
essential.
Method—We propose an approach to distribute smoking-attributable expenditures by age, 
gender, and cigarette smoking status to reflect the known risks of smoking. We distribute 
hospitalization days for smoking-attributable diseases according to relative risks of smoking-
attributable mortality, and use the method to determine national estimates of smoking-attributable 
expenditures by age, sex, and cigarette smoking status. Sensitivity analyses explored assumptions 
of the method.
Results—Both current and former smokers ages 75 and over have about 12 times the smoking-
attributable expenditures of their current and former smoker counterparts 35–54 years of age. 
Within each age group, the expenditures of formers smokers are about 70% lower than current 
smokers. In sensitivity analysis, these results were not robust to large changes to the relative risks 
of smoking-attributable mortality which were used in the calculations.
Conclusion—Sex- and age-group-specific smoking expenditures reflect observed disease risk 
differences between current and former cigarette smokers and indicate that about 70% of current 
smokers’ excess medical care costs is preventable by quitting.
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January 11th, 2014, marked the 50th anniversary of the release of the first Surgeon 
General’s Report on Smoking and Health in 1964 (Surgeon General’s Advisory Committee 
on Smoking and Health, 1964). While cigarette smoking continues to decline and millions of 
premature deaths were averted as a result of tobacco control efforts during the last half of 
the century (Centers for Disease Control and Prevention, 2011; Holford et al., 2014), 
tobacco use remains the nation’s leading preventable cause of death and disease (Surgeon 
General’s Advisory Committee on Smoking and Health, 1964). Annual smoking-attributable 
economic costs in the United States estimated for the years 2009–2012 were between $289 
and 332.5 billion, including $132.5–175.9 billion for direct medical care of adults (Centers 
for Disease Control and Prevention, 2008; Congressional Budget Office, 2012; Levy DE, 
2011; Miller et al., 1999; Solberg et al., 2006; U.S. Department of Health and Human 
Services, 2014; Warner et al., 1999). Therefore, concerted efforts, including tobacco price 
increases, high-impact anti-tobacco mass media campaigns, comprehensive smoke-free 
laws, and barrier-free access to help quitting, are needed to reduce tobacco use initiation and 
promote cessation.
To accurately assess the benefits of these interventions and to better inform decision makers, 
knowledge of medical expenditures by age, gender, and smoking status is essential. This 
paper provides age-group estimates of smoking-attributable medical expenditures based on 
nationally representative data for policy analyses. Individual-level observational data are 
complicated by spikes in medical utilization of recent quitters whose cessation was likely 
prompted by symptoms of smoking-attributable diseases (Centers for Disease Control and 
Prevention, 2008; Fishman et al., 2003, 2006; Hockenberry et al., 2012; Miller et al., 1999). 
Accuracy in the economic analysis of preventive interventions requires knowledge of what 
utilization would have been for all former smokers had they quit prior to symptoms. 
Moreover, timing of quits in the lifecycle is critical as it affects subsequent medical 
utilization (Jha et al., 2013; Woloshin et al., 2008). For example, comprehensive smoke-free 
laws may induce smokers to quit at an earlier age and prior to the development of smoking-
attributable illness. To assess the economic impact of these earlier quits, policy analysts 
need information on the age-specific difference in medical costs between continuing 
smokers and former smokers who quit for reasons other than having developed symptoms of 
a smoking-attributable illness.
This analysis, aligned with the 2014 Surgeon General’s Report on the health consequences 
of smoking (U.S. Department of Health and Human Services, 2014), provides an option for 
evaluating smoking-attributable expenditures by age, gender, and smoking status that 
reflects the known risks of smoking derived from epidemiological data and the benefits of 
cessation or averted initiation. Studies evaluating financial benefits of smoking prevention 
policies may adopt this method to be better aligned with health benefits of these 
interventions.
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Our method distributes smoking-attributable medical expenditures by age group, sex, and 
smoking status based upon the portion of disease events that occur among never, current, 
and former smokers. We first assess the distribution of smoking-attributable disease events 
in the US population by age and sex. Relative risks of events among never, current, and 
former smokers are then used to distribute events by smoking status within age and sex 
groups. For current and former smokers, the portion of events that occur in each age-sex 
strata is then calculated. These portions are used as a proxy for the distribution of smoking-
attributable expenditures by age, sex, and smoking status strata. We demonstrate use of 
these portions by applying a national estimate of smoking-attributable costs.
We use the distribution of hospitalization days for smoking-attributable conditions as a 
proxy for the distribution of total smoking-attributable expenditures. Facility bills for 
hospitalizations comprise 38% of all US personal health care expenditures (Office of the 
Actuary in the Centers for Medicare & Medicaid Services, 2012). The portion of all 
smoking-attributable expenditures that are for hospitalizations is approximately 51% 
(Centers for Disease Control and Prevention, 2007). Other services, including physician 
services provided during hospitalizations, are correlated with hospitalization expense. Using 
the 1987 National Medical Expenditure Survey, Miller et al. observed substantial agreement 
between the smoking-attributable portion of hospital expenditures and other types of care 
(Miller et al., 1999). They found smoking to be associated with 7.4% and 6.7% of hospital 
expenditures for ages 35–64 and ages 65 and greater, respectively, and for the same two age 
groups, smoking was associated with 11.2% and 10.9% of ambulatory expenditures, 7.7% 
and 8.4% of prescription drug expenditures and 7.2% and 7.6% of other medial 
expenditures. Using hospitalizations as a proxy for all expenditures has the advantages of a 
readily available and periodically updated public use, nationally representative data set. 
Estimates based on hospitalizations can be updated as the relative risks of smoking on 
medical conditions evolve. More importantly, hospitalizations are coded with a primary 
discharge diagnosis that allows each appropriate stay to be mapped to a smoking-attributable 
condition. In contrast, most outpatient encounters, nursing home care, and many 
pharmaceuticals cannot be readily attributed to a primary diagnosis. We distribute 
hospitalization days using disease-specific relative risks of smoking-attributable mortality by 
age and sex for current and former cigarette smokers compared to never smokers. The 
distribution of hospitalization days by population group is determined through calculation of 
smoking-attributable fractions. Calculations are provided in the technical appendix.
Data and sources
The method relies on an external estimate of national smoking-attributable medical 
expenditures, but can be applied to any number of such estimates. Following the latest 
evidence on smoking-attributable fractions in the U.S. healthcare spending (Solberg et al., 
2006; Xu et al., 2015), we use 8.66% of projected 2013 Personal Health Care Expenditures 
(PHCE) for adults 19 years of age and older less dental care in our example, which is 
consistent with previous cross-sectional studies that reported smoking-attributable fractions 
ranging from 6.5% to 14% (Miller et al., 1999; Warner et al., 1999). However, any 
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estimated attributable fractions based on studies published within the last 15 years can be 
used with this approach (Centers for Disease Control and Prevention, 2002; Congressional 
Budget Office, 2012; Levy DE, 2011; Miller et al., 1999; Solberg et al., 2006; Warner et al., 
1999).
We used the 2012 National Health Interview Survey to determine the distribution of the US 
population by age, sex, and smoking status. NHIS is an annual, nationally representative, in-
person survey of the noninstitutionalized U.S. civilian population aged 18 years or older. 
Current- and never-smoker status was determined using common definitions based upon 
having ever-smoked 100 or more cigarettes (Agaku et al., 2014).
We used first-listed discharge diagnosis code to identify inpatient stays in 2010 National 
Hospital Discharge Survey (NHDS), the most recent year of data available (Centers for 
Disease Control and Prevention, 2010). The NHDS is a national probability survey of 239 
hospitals that provides information on characteristics of inpatients discharged from US non-
Federal, general hospitals with an average length of stay of fewer than 30 days. Data from 
the sample of inpatients were weighted to produce national estimates and standard errors 
were tabulated using the generalized variance curves provided by NHDS for use in the 
public use data set (Centers for Disease Control and Prevention, 2012).
NHDS is abstracted from medical records that do not contain cigarette smoking status for 
use in calculating relative risks, and relative risks for nonfatal events are not available for a 
broad range of diseases from another standardized source. Therefore, mortality relative risks 
were used to distribute hospitalizations among never, current, and former smokers within 
age and gender groups. Relative risks of smoking-attributable mortality were obtained from 
the 2014 Surgeon General’s Report (U.S. Department of Health and Human Services, 2014) 
for age groups 35–54, 55–64, 65–74, and 75+ years as shown in Table 1. Compared to the 
relative risks reported in SAMMEC (Centers for Disease Control and Prevention, 2007), the 
relative risks used in our calculations were combined into fewer disease categories, 
reflecting the need to collapse on disease detail in order to expand on age detail using the 
same underlying data sets. Relative risks are assumed to equal 1.0 for ages below 35.
The use of mortality relative risks assumes that the event-fatality rate is constant across 
smoking status groups. If this is not the case, then our calculations may over-state or under-
state the financial benefits of quitting.
Sensitivity analysis
We explored modified methods by using any discharge diagnosis (rather than first listed) to 
identify hospital stays for smoking-attributable conditions and by using counts of stays 
rather than counts of days. In addition, because the method implicitly assigns equal weight 
to each day of care, we explored differential weighting to approximate the use of condition-
specific expenditures per day. For this, we assigned relative cost weights of 1.0 for 
cardiovascular disease, 2.0 for cancers, and 0.5 for respiratory disease to reflect the potential 
for cancer to have more intensive out-of-hospital treatments, and for respiratory conditions 
to be associated with relatively lower inpatient professional services. This hypothetical 
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scenario would imply substantial variation among conditions while still retaining the similar 
average proportion of smoking-attributable expenditures by care type as noted above.
Results
First-listed discharge diagnosis codes identified a total of 7.1 million hospitalizations and 
36.7 million hospitalization days for smoking-attributable conditions. The percent 
distribution of hospitalization days by condition for each age and sex strata are shown in 
Table 1. For all age groups, hospitalization days for cardiovascular conditions are the most 
frequent and therefore the relative risks for cardiovascular conditions have the greatest 
influence in the results.
Annual rates of smoking-attributable hospital days by age, sex, and smoking status are 
shown in Table 2. By subtracting hospitalization days that occurred in never smokers, and 
the portion that occurred in ever smokers that would have occurred even if they never started 
smoking, we estimate that 30% of the 36.7 million hospitalization days for the diseases 
included in the analysis are smoking-attributable (not shown). For all age groups, and for 
both males and females, estimated smoking-attributable hospitalization days for former 
smokers are about 30% of those of current smokers. The difference is larger for females in 
the 35–54 year age group.
For illustrative purposes, estimates of smoking-attributable expenditures by age, sex, and 
smoking status for 2012 are shown in Table 2 assuming 8.66% of PHCE are attributable to 
smoking (U.S. Department of Health and Human Services, 2014). Smoking-attributable 
expenditures of female smokers ages 35 to 54 years are $1,382 compared to $15,863 for 
their 75 years and older counterparts (cost ratio = 11.47). Similar ratios between the oldest 
and youngest age groups are seen across other sex and smoking status groups. The method, 
by its definition, yields the same relative difference in expenditures between former and 
current smokers as it does for hospitalization days.
Based upon the ratio of smoking-attributable expenditures of former smokers to current 
smokers when the average expenditures are weighted by each smoking groups’ age 
distribution, it might be mistakenly concluded that quitting reduces costs by 48% in men and 
47% in women (1–0.522 = .478; 1–0.531 = 0.469). However, the age distribution differs 
markedly between current and former smokers. Based upon average expenditures weighted 
by the age distribution of former smokers, we estimate that quitting reduces expenditures by 
approximately 72% in both men and women (1–0.282 = 0.718; 1–0.280 = 0.720).
Sensitivity analysis
Basing the estimates on hospitalizations rather than hospitalization days had little impact on 
the estimates. These results are shown in the first panel (SA 1) of Table 3. Using 
hospitalizations with a smoking-related disease diagnostic code in any position rather than 
first position has modest impact (SA 2).
The sensitivity analysis on weighting of hospitalizations to explore the implications of 
differences in care treatment costs found virtually no difference (Table 3 SA 3). The 
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increase in weights for cancers was offset by the decrease in weights for respiratory 
diseases. Therefore, we conducted an additional sensitivity analysis by doubling the weight 
of cardiovascular disease conditions. As shown in the fourth panel (SA 4), there was no 
pattern of change with respect to age group, but the difference in average smoking-
attributable expenditures between men and women was higher.
Finally, we increased all relative risks of both former and current smokers compared to 
never smokers by 50% (SA 5), and of former smokers alone (SA 6) to explore the potential 
impact of systematic bias caused by the use of mortality relative risks as a proxy for 
expenditure ratios. Increasing the relative risk of former smokers alone virtually eliminates, 
and in older strata reverses, the difference in relative risks between current and former 
smokers. This may indicate that the sensitivity analysis does not represent a realistic 
scenario as the results conflict with the evidence that smoking increases disease risk.
Discussion
For those who are interested in the impacts of smoking and quitting on smoking-attributable 
medical expenditure, we provide alternative estimates of smoking-attributable medical 
expenditures by age group, sex, and smoking status. Based on this approach, we have shown 
that smoking-attributable medical expenditures increase with age for both current smokers 
and former smokers. For those aged 55 years old and above, estimated smoking-attributable 
medical expenditures of former smokers were about 30% of those of their counterpart 
current smokers. These findings imply that, within each age and gender group, had smokers 
quit before having any symptoms of smoking-related diseases, approximately 70% of 
smoking-attributable expenditures could be avoided. The potential percent savings appear to 
be larger for females in the 35–54-year age group, in large part due to a higher risk of 
pulmonary disease among current smokers relative to former smokers.
The Congressional Budget Office (CBO) has provided per-person estimates by age by 
linking Medical Care Expenditure Survey (MEPS) data with NHIS data (Congressional 
Budget Office, 2012). The same data source also has been used to estimate national 
expenditures by age group or by payer but did not report per-person estimates (Levy DE, 
2011; Xu et al., 2015). Sloan et al. combined MEPS data with additional longitudinal data 
sources to provide a comprehensive estimate of smoking costs but they did not report age-
group estimates for former and current smokers as would be needed in evaluating policies 
that promote cessation (Sloan, 2004).
The MEPS-NHIS link provides a substantial sample with claims data linked to smoking 
history and allows analyses that control for differences among current, former, and never 
smokers. However, the MEPS-NHIS data also have limitations. The MEPS population is 
limited to non-institutionalized civilians who were alive at time of the survey and hence the 
data miss potentially important costs among those who died during the year. MEPS excludes 
costs for some services such as long-term care stays longer than 45 days. A comparison of 
2002 MEPS and Personal Health Care Expenditures (PHCE) found total expenditures for the 
nation based on MEPS to be 38% lower than PHCE (Sing et al., 2006). Like all claims data, 
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the MEPS data also exhibit spikes of utilization for recent quitters who may be motivated to 
quit by worsening health.
The estimated smoking-attributable expenditures by age group in our analysis were higher 
than those reported in the CBO report, which relies on the linked MEP:S-NHIS data 
(Congressional Budget Office, 2012). The smoking-attributable fraction used in this analysis 
is assumed to be 8.66% (U.S. Department of Health and Human Services, 2014), which is 
consistent with previous cross-sectional studies that reported smoking-attributable fractions 
ranging from 6.5% to 14% but higher than the 7% presented in the CBO report.
Although our analytical approach is consistent and can be easily updated with known 
disease impacts of smoking and quitting, we do not propose that this approach or estimates 
presented here are necessarily better than others available. Given the limitations of MEPS-
based estimates noted above and limitations of the approach proposed here, we encourage 
policy analysts to consider age-specific estimates of smoking-attributable costs from both 
sources to inform a plausible range of cost-inputs and to understand their impact on results. 
One limitation of this analytical approach is the use of relative risks of mortality of current 
and never smokers as a proxy for the relative risk of medical expenditures. Large differences 
between mortality-relative risks and expenditure-relative risks, such as those that might be 
observed if case-fatality rates differ substantially between never, current, and former 
smokers, produced meaningful differences in the relative costs of current and former 
smokers and somewhat impacted the magnitude of difference in smoking-attributable 
medical expenditures between younger and older current and former smokers. A second 
important limitation is reliance on hospitalization days as proxy for all utilization. While 
there is good correspondence between the portion of hospitalization expense attributable to 
smoking and other medical expenses, there may be variation in this portion among smoking-
attributable conditions. Although Miller et al. showed similar smoking-attributable fractions 
for the broad age groups of 35–64 and 65 and older (Miller et al., 1999), there may also be 
important variation between the 33–54 year and 75+ age groups reported in our results. 
While use of inpatient days provides a convenient data source for updating results and 
attribution of utilization to smoking-related conditions, undoubtedly estimates based on 
painstakingly assigning all forms of utilization to diagnostic codes through medical records 
review in a large, representative population would yield more precise estimates.
Other limitations explored in sensitivity analysis did not impact the estimates substantially. 
Using hospitalizations with a discharge diagnostic code for smoking-related condition in any 
position rather than just first-listed code did impact the age distribution of the expenditure. 
However, we believe that using the first-listed diagnosis code is more appropriate because it 
prevents coded comorbidities that are more common among all older adults, regardless of 
smoking status, from diluting the observed impact of smoking when it is the primary reason 
for the visit.
Finally, this analytical approach is focused on the evaluation of medical expenditures 
attributable to cigarettes smoking among adults only by age and gender. It does not consider 
potential medical expenditures associated with use of other combustible or non-combustible 
tobacco products, nor consider those related to maternal and child health or second-hand 
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smoke exposure. Given the diversification of the tobacco use landscape in recent years, the 
analysis doesn’t fully capture the overall medical expenditures resulting from all tobacco 
product use (Centers for Disease Control and Prevention, 2013).
Although our estimated smoking-attributable medical expenditures are subject to some 
limitations, they clearly indicate that former smokers have substantial lower smoking-
attributable medical costs than current smokers and the difference in costs increases with 
age. Since tobacco use remains the leading cause of preventable morbidity and mortality in 
the United States, continued implementation of evidence-based interventions outlined in the 
World Health Organization MPOWER package is critical (World Health Organization, 
2008). These include increasing the price of tobacco products, implementing and enforcing 
comprehensive smoke-free laws, warning about the dangers of tobacco use with 
antismoking media campaigns, and increasing access to help quitting (Centers for Disease 
Control and Prevention, 2014; Huang and Chaloupka, 2012; McAfee et al., 2013). Future 
regulatory action by the FDA, such as reducing nicotine to non-addictive levels in cigarettes, 
has further potential (U.S. Department of Health and Human Services, 2014). Additionally, 
sustained, comprehensive state tobacco control programs funded at CDC-recommended 
levels can also reduce the health burden and economic impact of tobacco-related diseases in 
the United States (Centers for Disease Control and Prevention, 2014).
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Annual hospitalization days for each smoking-attributable condition can be disaggregated by 
smoking status age group i, and sex j, according to the formula:
where Ni,j is the population size for each age i and sex j strata and Rh,i,j is their annual rate of 
hospitalization days for each smoking-attributable disease h. Smoking status S is defined by 
three values for k representing never (NS), current (CS), and former (FS) smokers. The rate 
of hospitalization days of never smokers for each condition known to be caused by smoking 
cigarettes is obtained by first multiplying the right-hand side of the equation by one in the 
form of Rh,i,j,NS/Rh,i, j,NS. Then substituting the relative risk of each smoking status k, age 
group and sex compared to never smokers of the same age and sex group (RRh,i, j,k = Rh,i, j,k/Rh,i, j,NS) and rearranging the equation yields:
The rate of hospitalizations days for current and former smokers is then computed by 
multiplying their relative rates by the rate of hospitalization days of never smokers.
For each age, sex, and smoking status group, the smoking-attributable rate of hospitalization 
days (SARi,j,k), is the sum across all smoking-attributable conditions of the difference in rate 
between each smoking status group rate and the rate of never smokers:
The SAR of never smokers is zero, by definition and mathematically. Finally, the 
distribution of hospitalization days is used to allocate smoking-attributable expenditures by 
age group, sex and smoking status. For each population group, an estimate of national 
smoking-attributable medical expenditures (SAME) was multiplied by the percent of all 
smoking-attributable hospitalizations occurring in that group. That product was divided by 
group size to obtain per-person expenditures by age, sex, and smoking status:
Where SAME-Ii, j,k is the annual smoking-attributable medical expenditures of an individual 
of age group i, sex j, and smoking status k.
In sensitivity analysis, the calculation of weighted smoking-attributable risk (WSAR) was 
determined by:
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where wh is the relative weight for condition h. Finally, we systematically altered relative 
risks to test the implicit assumption that event-fatality rates are constant by smoking status.
Maciosek et al. Page 11



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Prev Med. Author manuscript; available in PMC 2016 August 01.
